The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents

Christoph U Correll^{1

2

3

4}, Marco Solmi^{1

5

6

7

8

9}, Samuele Cortese^{9

10

11

12

13}, Maurizio Fava¹⁴, Mikkel Højlund^{15

16}, Helena C Kraemer¹⁷, Roger S McIntyre^{18

19

20

21

22

23}, Daniel S Pine²⁴, Lon S Schneider²⁵, John M Kane^{2

3

4}

Affiliations

¹ Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany.
² Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.
³ Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
⁴ Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA.
⁵ Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
⁶ Department of Mental Health, Ottawa Hospital, Ottawa, ON, Canada.
⁷ Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program, University of Ottawa, Ottawa, ON, Canada.
⁸ School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
⁹ Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK.
¹⁰ Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK.
¹¹ Solent NHS Trust, Southampton, UK.
¹² Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK.
¹³ Hassenfeld Children's Hospital at NYU Langone, New York University Child Study Center, New York, NY, USA.
¹⁴ Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
¹⁵ Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.
¹⁶ Mental Health Services in the Region of Southern Denmark, Department of Psychiatry Aabenraa, Aabenraa, Denmark.
¹⁷ Department of Psychiatry and Behavioral Sciences, Stanford University, Cupertino, CA, USA.
¹⁸ Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
¹⁹ Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
²⁰ Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
²¹ Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
²² Department of Pharmacology, University of Toronto, Toronto, ON, Canada.
²³ Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
²⁴ Section on Developmental Affective Neuroscience, National Institute of Mental Health, Bethesda, MD, USA.
²⁵ Department of Psychiatry and Behavioral Sciences, and Department of Neurology, Keck School of Medicine, and L. Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.

PMID: 36640403
PMCID: PMC9840514
DOI: 10.1002/wps.21056

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents

Christoph U Correll et al. World Psychiatry. 2023 Feb.

. 2023 Feb;22(1):48-74.

doi: 10.1002/wps.21056.

Authors

Affiliations

¹ Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany.
² Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.
³ Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
⁴ Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA.
⁵ Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
⁶ Department of Mental Health, Ottawa Hospital, Ottawa, ON, Canada.
⁷ Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program, University of Ottawa, Ottawa, ON, Canada.
⁸ School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
⁹ Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK.
¹⁰ Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK.
¹¹ Solent NHS Trust, Southampton, UK.
¹² Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK.
¹³ Hassenfeld Children's Hospital at NYU Langone, New York University Child Study Center, New York, NY, USA.
¹⁴ Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
¹⁵ Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.
¹⁶ Mental Health Services in the Region of Southern Denmark, Department of Psychiatry Aabenraa, Aabenraa, Denmark.
¹⁷ Department of Psychiatry and Behavioral Sciences, Stanford University, Cupertino, CA, USA.
¹⁸ Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
¹⁹ Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
²⁰ Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
²¹ Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
²² Department of Pharmacology, University of Toronto, Toronto, ON, Canada.
²³ Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
²⁴ Section on Developmental Affective Neuroscience, National Institute of Mental Health, Bethesda, MD, USA.
²⁵ Department of Psychiatry and Behavioral Sciences, and Department of Neurology, Keck School of Medicine, and L. Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.

PMID: 36640403
PMCID: PMC9840514
DOI: 10.1002/wps.21056

Abstract

Despite considerable progress in pharmacotherapy over the past seven decades, many mental disorders remain insufficiently treated. This situation is in part due to the limited knowledge of the pathophysiology of these disorders and the lack of biological markers to stratify and individualize patient selection, but also to a still restricted number of mechanisms of action being targeted in monotherapy or combination/augmentation treatment, as well as to a variety of challenges threatening the successful development and testing of new drugs. In this paper, we first provide an overview of the most promising drugs with innovative mechanisms of action that are undergoing phase 2 or 3 testing for schizophrenia, bipolar disorder, major depressive disorder, anxiety and trauma-related disorders, substance use disorders, and dementia. Promising repurposing of established medications for new psychiatric indications, as well as variations in the modulation of dopamine, noradrenaline and serotonin receptor functioning, are also considered. We then critically discuss the clinical trial parameters that need to be considered in depth when developing and testing new pharmacological agents for the treatment of mental disorders. Hurdles and perils threatening success of new drug development and testing include inadequacy and imprecision of inclusion/exclusion criteria and ratings, sub-optimally suited clinical trial participants, multiple factors contributing to a large/increasing placebo effect, and problems with statistical analyses. This information should be considered in order to de-risk trial programmes of novel agents or known agents for novel psychiatric indications, increasing their chances of success.

Keywords: Psychopharmacology; anxiety disorders; bipolar disorder; clinical trials; dementia; design; major depressive disorder; methodology; novel mechanisms of action; schizophrenia; substance use disorders; trauma-related disorders.

PubMed Disclaimer

References

1. Dragioti E, Radua J, Solmi M et al. Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta‐umbrella systematic review. Mol Psychiatry 2022; doi: 10.1038/s41380-022-01586-8. - DOI - PMC - PubMed
1. Fusar‐Poli P, Correll C, Arango C et al. Preventive psychiatry: a blueprint for improving the mental health of young people. World Psychiatry 2021;20:200‐21. - PMC - PubMed
1. Salazar de Pablo G, De Micheli A, Solmi M et al. Universal and selective interventions to prevent poor mental health outcomes in young people: systematic review and meta‐analysis. Harv Rev Psychiatry 2021;29:196‐215. - PubMed
1. Solmi M, Dragioti E, Arango C et al. Risk and protective factors for mental disorders with onset in childhood/adolescence: an umbrella review of published meta‐analyses of observational longitudinal studies. Neurosci Biobehav Rev 2021;120:565‐73. - PubMed
1. Maj M, Stein DJ, Parker G et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry 2020;19:269‐93. - PMC - PubMed

Grants and funding

P30 AG066530/AG/NIA NIH HHS/United States

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents

Affiliations

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents

Authors

Affiliations

Abstract

References

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous